Research programme: tyrosine kinase inhibitors - Ocular Therapeutix

Drug Profile

Research programme: tyrosine kinase inhibitors - Ocular Therapeutix

Alternative Names: OTX-TKI

Latest Information Update: 24 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ocular Therapeutix
  • Class Eye disorder therapies; Small molecules
  • Mechanism of Action Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diabetic macular oedema; Retinal vein occlusion; Wet age-related macular degeneration

Most Recent Events

  • 07 Nov 2017 Ocular Therapeutix plans a phase I trial in Wet age-related macular degeneration outside the U.S in the first half of 2018
  • 09 May 2017 Pharmacodynamics data from a preclinical trial in Wet age-related macular degeneration released by Ocular Therapeutix
  • 10 Mar 2017 Preclinical trials in Diabetic macular oedema in USA (Intravitreous)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top